文献速递青光眼

他氟噻吗固定复方对比他氟前列素单药治疗开角型青光眼与高眼压症的多中心随机双盲试验

[Tafluprost/timolol fixed-dose combination versus tafluprost monotherapy for open-angle glaucoma and ocular hypertension: a multicenter, randomized, double-blind, parallel-group trial].
PubMed 文献 · Zhonghua Yan Ke Za Zhi · 2026-01-01

中国25中心纳入219例OAG或高眼压症患者,随机接受无防腐剂他氟噻吗固定复方或他氟前列素单药每日1次治疗3个月。第3个月平均日间眼压降幅组间差异为-1.312 mmHg(95%CI:-2.010~-0.696),他氟噻吗优效于单药,且眼部不良事件发生率较低。

要点

  • 他氟噻吗固定复方降眼压效果优效于他氟前列素单药。
  • 他氟噻吗组结膜充血发生率2.7%,低于单药组8.3%。
  • 眼压降幅≥15%、≥25%、≥30%的应答率复方组均显著更高。

核心结论

  • 与无防腐剂他氟前列素单药相比,他氟噻吗固定复方治疗OAG及高眼压症降眼压疗效更显著且安全性良好。

研究设计与样本

  • 多中心、随机、双盲、平行对照临床试验,2019年1月至2022年11月在包括复旦大学附属眼耳鼻喉科医院在内的25个中心开展。
  • 纳入219例OAG或高眼压症患者,按1∶1随机分配至他氟噻吗组(n=110)或他氟前列素组(n=109),每日点眼1次治疗3个月。
  • 主要疗效分析集纳入215例(他氟噻吗组107例,他氟前列素组108例)。

主要发现

  • 治疗第3个月,他氟噻吗组平均日间眼压较基线下降(6.56±3.44)mmHg,他氟前列素组下降(5.36±2.94)mmHg。
  • 经基线眼压校正后组间差异为-1.312 mmHg(95%CI:-2.010~-0.696),95%CI上限<0 mmHg,他氟噻吗优效于他氟前列素。
  • 眼压降幅≥15%、≥25%和≥30%的应答者比例在他氟噻吗组均显著高于他氟前列素组(P=0.016、0.028、0.032)。
  • 眼部相关不良事件发生率他氟噻吗组为20.0%(22/110),他氟前列素组为26.6%(29/109)。
  • 最常见不良事件为结膜充血,他氟噻吗组发生率为2.7%(3/110),他氟前列素组为8.3%(9/109)。

关键数值与推荐

  • 主要终点优效性判定标准为组间差异95%CI上限<0 mmHg(1 mmHg=0.133 kPa)。
  • 主要终点采用基于MCMC方法的协方差分析,次要终点计量资料用协方差分析,应答者比例用Fisher精确检验。

临床怎么用

  • 对于OAG或高眼压症需强化降眼压治疗的患者,可优先考虑无防腐剂他氟噻吗固定复方每日1次方案。
  • 复方方案在提升降眼压幅度的同时结膜充血发生率更低,可能有利于长期用药耐受性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To evaluate the efficacy and safety of a preservative-free tafluprost/timolol maleate fixed-dose combination compared with preservative-free tafluprost monotherapy in Chinese patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). Methods: This was a multicenter, randomized, double-blind, parallel-controlled clinical trial conducted across 25 centers, including the Eye & ENT Hospital of Fudan University, from January 2019 to November 2022. Patients diagnosed with OAG or OHT who required enhanced intraocular pressure (IOP) reduction after a 4-week washout period were enrolled. Participants were randomized 1∶1 to receive either tafluprost/timolol or tafluprost once daily for 3 months. The primary endpoint was the change from baseline in mean diurnal IOP (the average of measurements at 8:00, 10:00, and 16:00) at Month 3. Secondary endpoints included IOP changes at individual time points and the proportion of responders achieving predefined IOP reduction thresholds. Safety was assessed via the incidence of adverse events (AEs). Analysis of covariance (ANCOVA) using the Markov Chain Monte Carlo (MCMC) method was employed for the primary endpoint; superiority was established if the upper limit of the 95% confidence interval (CI) was<0 mmHg (1 mmHg=0.133 kPa). Continuous variables in secondary endpoints were compared using ANCOVA, and responder rates were analyzed using Fisher's exact test. Results: A total of 219 patients were enrolled (tafluprost/timolol group: n=110; tafluprost group: n=109). The primary efficacy analysis set included 215 patients (tafluprost/timolol: n=107; tafluprost: n=108). Baseline characteristics were well-balanced between the two groups. The majority of patients were male [127 (59.1%)] with a mean age of (44.80±15.71) years at screening. At Month 3, the mean diurnal IOP reduction from baseline was (6.56±3.44) mmHg in the tafluprost/timolol group and (5.36±2.94) mmHg in the tafluprost group. After adjusting for baseline IOP, the between-group difference was -1.312 mmHg (95%CI: -2.010 to -0.696); as the upper limit was<0 mmHg, tafluprost/timolol demonstrated superior IOP-lowering efficacy to tafluprost. Responder rates for IOP reductions of≥15%,≥25%, and≥30% were significantly higher in the tafluprost/timolol group (P=0.016, 0.028, and 0.032, respectively). The incidence of ocular AEs was 20.0% (22/110) in the tafluprost/timolol group and 26.6% (29/109) in the tafluprost group. The most common AE was conjunctival hyperemia, occurring in 2.7% (3/110) and 8.3% (9/109) of the groups, respectively. Conclusion: Compared with preservative-free tafluprost monotherapy, the tafluprost/timolol combination provides significantly greater IOP reduction in patients with OAG and OHT, while maintaining a favorable safety profile. 目的: 评估无防腐剂他氟前列素/马来酸噻吗洛尔固定复方(他氟噻吗)对比无防腐剂他氟前列素单药,在中国开角型青光眼(OAG)及高眼压症患者中的降眼压疗效与安全性。 方法: 多中心、随机、双盲、平行对照临床试验。纳入2019年1月至2022年11月于复旦大学附属眼耳鼻喉科医院等25个研究中心就诊,诊断为OAG或高眼压症且在4周洗脱期后仍需强化降眼压治疗的患者。按1∶1比例随机分配至他氟噻吗组或他氟前列素组,均每日点眼1次,治疗3个月。主要终点为治疗第3个月时平均日间眼压(8:00、10:00、16:00测量值的均值)较基线的变化。次要终点包括各时间点眼压较基线变化值及达到预设眼压降幅阈值的应答者比例等。安全性终点为不良事件发生率。主要终点采用基于马尔科夫链蒙特卡洛(MCMC)方法的协方差分析,以95%置信区间上限<0 mmHg(1 mmHg=0.133 kPa)为优效性判定标准;次要终点中,计量资料的组间比较采用协方差分析,应答者比例的组间比较采用Fisher精确检验。 结果: 共纳入219例患者,他氟噻吗组110例(110只眼),他氟前列素组109例(109只眼)。主要疗效分析集纳入215例受试者,其中他氟噻吗组107例、他氟前列素组108例。两组基线特征均衡可比。受试者以男性为主[127例(59.1%)],年龄为(44.80±15.71)岁。治疗第3个月时,他氟噻吗组和他氟前列素组平均日间眼压较基线分别下降(6.56±3.44)和(5.36±2.94)mmHg。经基线眼压校正后,组间差异为-1.312 mmHg(95%置信区间:-2.010~-0.696);区间上限<0 mmHg,他氟噻吗降眼压效果优效于他氟前列素。眼压降幅≥15%、≥25%和≥30%的应答者比例在他氟噻吗组均显著高于他氟前列素组(P=0.016、0.028、0.032)。两组治疗后眼部相关不良事件发生率分别为20.0%(22/110)和26.6%(29/109);占比最高的不良事件为结膜充血,发生率分别为2.7%(3/110)和8.3%(9/109)。 结论: 与无防腐剂他氟前列素单药治疗相比,他氟噻吗治疗OAG及高眼压症降眼压疗效更显著,且安全性良好。.

来源:Zhonghua Yan Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Wang KD, Zhao P, Wu LL, et al. [Tafluprost/timolol fixed-dose combination versus tafluprost monotherapy for open-angle glaucoma and ocular hypertension: a multicenter, randomized, double-blind, parallel-group trial]. Zhonghua Yan Ke Za Zhi. 2026. PMID: 42706141. doi:10.3760/cma.j.cn112142-20251230-00559

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。